KEY POINTS
- This retrospective single-center study included 378 patients with localized prostate cancer treated with external-beam radiotherapy (EBRT) plus HDR brachytherapy boost between 2004 and 2016. Median follow-up was 130.1 months (10.8 years). Patients were treated as high risk according to historical institutional criteria; when regrouped by current NCCN-based definitions, 58.2% were high risk, 17.2% very high risk, and 24.6% belonged to other categories. Nearly all patients (92.3%) received androgen deprivation therapy.
- Two consecutive institutional protocols were compared, rather than randomized treatment strategies. Before November 2009, 205 patients received 46 Gy in 23 fractions of EBRT followed by an HDR boost of 9–10 Gy × 2, with both fractions delivered eight hours apart using one implant and the same plan. From November 2009, 173 patients received 15 Gy × 1 HDR followed by the same EBRT prescription. The later cohort also routinely received a hyaluronic acid rectal spacer, meaning that fractionation, sequencing, treatment era, and spacer use were strongly confounded.
- Ten-year oncologic outcomes showed no statistically significant differences. Biochemical recurrence-free survival was 79.6% after one HDR fraction versus 82.6% after two (p=0.784). Corresponding metastasis-free survival was 90.5% versus 91.6% (p=0.839), and prostate cancer-specific survival was 95.3% versus 95.4% (p=0.992). Across the full cohort, ten-year biochemical recurrence-free survival, metastasis-free survival, and cancer-specific survival were 81.4%, 91.5%, and 95.4%, respectively. These nonsignificant differences do not demonstrate treatment equivalence.
- Severe urinary toxicity was more frequent in the historical two-fraction cohort. Crude grade ≥3 genitourinary toxicity occurred in 47/205 patients (22.9%) after two fractions versus 18/173 (10.4%) after one (p=0.002). However, ten-year freedom from grade ≥3 GU toxicity was 82.2% versus 89.7% (p=0.076), respectively, without a statistically significant time-to-event difference. Most severe GU events (92.3%) occurred more than three months after treatment, including urinary retention, stricture, and procedures requiring urethral intervention.
- Severe gastrointestinal toxicity remained uncommon. Grade ≥3 GI events occurred in 1.6% of the full cohort, with ten-year freedom from severe GI toxicity of 99.4% after one fraction versus 98.3% after two (p=0.442). For the historical two-fraction protocol, the second HDR fraction was delivered without repeat imaging or replanning, and no cumulative urethral or rectal dose limit was applied across the two fractions. These factors may have contributed to toxicity, but individual delivered OAR doses were unavailable.
- Baseline risk and follow-up duration differed between treatment cohorts. Clinical T3 disease was more common after one fraction (72.3% versus 43.4%), as was NCCN high or very-high-risk disease (84.4% versus 67.8%). Median follow-up was shorter after one fraction (110.6 versus 149.2 months). On multivariable analysis, higher baseline PSA and Gleason score >7 predicted biochemical recurrence and cancer-specific outcomes, while T3b stage was associated with worse biochemical control. Fraction number was not a statistically significant independent predictor, although confidence intervals remained wide.
- The findings apply specifically to HDR boost combined with EBRT, not HDR monotherapy. The protocol change also altered EBRT sequencing, rectal spacer use, and potentially urethral exposure, making it impossible to isolate the effect of fraction number. The authors specifically distinguish their findings from randomized HDR monotherapy evidence, where a single fraction produced inferior local control compared with two fractions. A requirement for at least two years of follow-up and historical three-dimensional conformal EBRT further limit generalizability.
CLINICAL TAKEAWAY
A single 15-Gy HDR brachytherapy boost combined with EBRT produced favorable long-term outcomes in this retrospective cohort, without a statistically significant difference in biochemical control compared with two HDR fractions. Severe urinary toxicity was more frequent with the historical two-fraction protocol, but treatment era, sequencing, and dosimetric factors prevent attributing this difference to fractionation alone. These findings support further evaluation of single-fraction HDR boost, without establishing equivalence or applicability to HDR monotherapy.